Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI (Q33803473)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI (English)

1 reference

Europe PubMed Central

29 July 2017

Andrea Costantini

object named as

Andrea Costantini

12

0 references

Antonella Castagna

object named as

Antonella Castagna

9

0 references

object named as

Andrea De Luca

7

0 references

Andrea Antinori

6

object named as

Andrea Antinori

1 reference

Europe PubMed Central

29 July 2017

Antonella d'Arminio Monforte

2

object named as

Antonella d'Arminio-Monforte

1 reference

Europe PubMed Central

29 July 2017

Giampiero Carosi

13

object named as

Giampiero Carosi

1 reference

Europe PubMed Central

29 July 2017

Cristina Mussini

8

object named as

Cristina Mussini

1 reference

Europe PubMed Central

29 July 2017

1

object named as

Carlo Torti

1 reference

Europe PubMed Central

29 July 2017

author name string

Anton L Pozniak

3

1 reference

Europe PubMed Central

29 July 2017

Giuseppe Lapadula

4

1 reference

Europe PubMed Central

29 July 2017

Giuliana Cologni

5

1 reference

Europe PubMed Central

29 July 2017

Paola Cicconi

10

1 reference

Europe PubMed Central

29 July 2017

Lorenzo Minoli

11

1 reference

Europe PubMed Central

29 July 2017

Hua Liang

14

1 reference

Europe PubMed Central

29 July 2017

Bruno M Cesana

15

1 reference

Europe PubMed Central

29 July 2017

MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts

16

1 reference

Europe PubMed Central

29 July 2017

publication date

25 January 2011

1 reference

Europe PubMed Central

29 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

29 July 2017

11

1 reference

Europe PubMed Central

29 July 2017

23

1 reference

Europe PubMed Central

29 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

25 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1471-2334-11-23

0 references

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

Evaluation of change in CD4+ cell counts in AIDS clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

The cost-effectiveness of preventing AIDS-related opportunistic infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038912

4 July 2018

Incidence of Malignancies in HIV‐Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Protease inhibitors as immunomodulatory drugs for HIV infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Stability of antiretroviral regimens in patients with viral suppression

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

The central role of the propensity score in observational studies for causal effects

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

2 references

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/21266068

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mixed-Effects Models in Sand S-PLUS

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-11-23

21 January 2018

Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/21266068

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21266068

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-11-23

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

release_cyydw4pc4vfzpmilmdmdog7ymq

1 reference

https://api.fatcat.wiki/v0/release/cyydw4pc4vfzpmilmdmdog7ymq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33803473&oldid=1899120005"